INTRODUCTION
============

Treatment with a very-low-calorie diet (VLCD; \<800 kcal/d) or low-calorie diet (LCD; \<1200 kcal/d) is associated with substantial initial weight loss, but also greater weight regain compared with weight loss achieved through a more moderate restriction in energy intake ([@bib1], [@bib2]). Maintaining a large weight loss requires substantial behavioral efforts, especially when nonbariatric surgical methods are used ([@bib3], [@bib4]).

Effects of different maintenance strategies after a VLCD have been tested in randomized trials, such as anti-obesity drugs ([@bib5]--[@bib9]), meal replacements ([@bib10], [@bib11]), high-protein diets ([@bib12]--[@bib17]), low-glycemic-index diets ([@bib15]), low-fat diets ([@bib18]), green tea extracts ([@bib14], [@bib19]), a prolonged refeeding period ([@bib20]), waist corsets ([@bib21]), and exercise ([@bib22], [@bib23]). The effects of these maintenance strategies remain unclear, and previous meta-analyses that investigated long-term effects of a VLCD have only compared the effects of VLCDs with LCDs ([@bib1], [@bib24]).

The aim of this systematic review and meta-analysis was to quantify the effects of anti-obesity drugs, diet, and exercise on weight-loss maintenance after a VLCD or LCD. We included randomized controlled trials in which all participants started with a VLCD or LCD (caloric intake cutoff set at \<1000 kcal/d) and thereafter were randomly assigned to either a maintenance strategy or control or placebo.

MATERIALS AND METHODS
=====================

Data sources and searches
-------------------------

A systematic search of 3 bibliographic databases \[MEDLINE (<http://www.ncbi.nlm.nih.gov/pubmed>), EMBASE (<http://www.embase.com>), and Cochrane Controlled Trials Register (<http://www.thecochranelibrary.com>)\] from 1981 to February 2013 was performed by using 3 search strings: *1*) "VLED" or "VLCD" or "very low energy diet" or "very low calorie diet," *2*) "LED" or "LCD" or "low energy diet" or "low calorie diet," and *3*) "weight loss maintenance" or "maintained weight loss" or "weight maintenance" or "weight regain." The search was limited to humans, randomized controlled trials, English language publications, and adults in the databases where limitations were possible (MEDLINE and EMBASE). The reference lists of identified articles were also searched for additional studies, as were reference lists of previously published reviews. Two reviewers (KJ and EH) separately screened the abstracts for inclusion or exclusion. Full text articles were retrieved from all abstracts that were potentially relevant and were reviewed independently by the 2 researchers. In case of conflicting views, a third researcher (MN) was asked to resolve the conflict.

Study selection
---------------

Studies were included if they were randomized controlled trials of adults (age ≥18 y), and consisted of an initial weight-loss period with a VLCD or LCD (\<1000 kcal/d) followed by randomization to a maintenance strategy (anti-obesity drug, diet, and/or exercise) or control. No restrictions regarding study duration were imposed. Studies were excluded if they evaluated anti-obesity drugs that never reached approval by regulatory agencies or if the weight-loss period did not include a VLCD or LCD. Sibutramine and rimonabant were eligible for inclusion because they had been approved and widely used as anti-obesity drugs before being withdrawn from the market in 2010 and 2009, respectively.

Data extraction and quality assessment
--------------------------------------

Data on participants, interventions, weight loss, and weight-loss maintenance were extracted by 2 researchers (KJ and EH) independently by using predefined data templates. Disagreements were resolved through discussion. For the meta-analysis, data on number of subjects and mean changes with corresponding SDs in the intervention and control arm were extracted. Many studies did not report these values. In those cases, SDs and mean changes were calculated from other data (*see* "Supplemental data" in the online issue).

Five studies included \>2 arms ([@bib14], [@bib15], [@bib18], [@bib25], [@bib26]). Weighted mean differences were calculated between the 2 groups that showed the most resemblance to other studies in the treatment category. Larsen et al ([@bib15]) reported both the isolated and combined effects of a high-protein diet and a low-glycemic-index diet. In the meta-analysis, the isolated main effects of high protein compared with low protein and low glycemic index compared with high glycemic index were included. Due et al ([@bib18]) reported the effect of 2 interventions (low fat and the Healthy Eating Pyramid, which is high in MUFAs and has a low glycemic index), and both treatment arms were included and compared with the control group. In the study by Hursel et al ([@bib14]), the green tea effect was analyzed by comparing the green tea/adequate-protein group with the placebo/adequate-protein group, and the high-protein effect was analyzed by comparing the green tea/high-protein with the green tea/adequate-protein group. The study by Kamphuis et al ([@bib25]) included 2 different doses of conjugated linoleic acid (1.8 and 3.6 g) compared with placebo (1.8 and 3.6 g). Both doses were included.

Two reviewers (KJ and EH) independently evaluated the individual studies regarding the extent of loss to follow-up and the adequacy of randomization and concealment of allocation, blinding of patients, data collectors, and outcome assessors.

Data synthesis and analysis
---------------------------

### Primary outcome

The primary outcome was the weighted mean difference in weight change (kg) during the weight-loss maintenance phase between the intervention and control groups. The random-effects model was used to weight and pool the studies within each maintenance category (anti-obesity drug, diet, and exercise). The diet studies were further subdivided into high-protein diet, meal replacement, dietary supplements, and macronutrients other than protein, including low glycemic index, low fat, and eating according to the Healthy Eating Pyramid.

Heterogeneity between studies was assessed by the *I*^2^ statistic ([@bib27]), and if this exceeded 50% or was statistically significant, the reasons for heterogeneity were explored by subgroup analyses or meta-regression. Low, moderate, and high heterogeneity were defined according to cutoffs of 25%, 50%, and 75%, respectively ([@bib28]). To investigate possible publication bias, a funnel plot of the inverse of the SE was inspected visually, and statistical significance was calculated by using Egger\'s test ([@bib29]).

### Secondary outcome

A secondary aim was to illustrate weight change after the VLCD or LCD phase and weight-loss maintenance phase within each treatment arm. The random-effects model was used to weight and pool the weight changes within each treatment and control arm during the maintenance period. The mean monthly change was estimated from these 2 measurements. The statistical analyses were conducted by using Comprehensive Meta Analysis (version 2; Biostat Inc). *P* values \<0.05 were regarded as statistically significant.

RESULTS
=======

Study selection
---------------

The systematic search resulted in 20 randomized controlled trials that met the inclusion criteria ([**Figure 1**](#fig1){ref-type="fig"}), which included 27 intervention arms with 3017 participants. Of these, 3 arms evaluated anti-obesity drugs (*n* = 658), 4 meal replacements (*n* = 322), 6 high-protein diets (*n* = 865), 6 dietary supplements (*n* = 261), 3 other diets (*n* = 564), and 5 exercise (*n* = 347).

![Flowchart of included studies. RCT, randomized controlled trial.](ajcn99114fig1){#fig1}

Study characteristics
---------------------

### Participants

Participant characteristics were similar, with a greater proportion of women than men in most of the studies ([**Table 1**](#tbl1){ref-type="table"}). The mean age ranged between 28 and 48 y and mean BMI (kg/m^2^) between 27.9 and 41.6. All studies but one were from Europe; most were from the Netherlands ([@bib6], [@bib12], [@bib14], [@bib16], [@bib17], [@bib19], [@bib25], [@bib30]) and Scandinavia ([@bib7], [@bib10], [@bib11], [@bib18], [@bib20], [@bib22], [@bib23], [@bib26], [@bib31]), and the remaining 3 studies were from France ([@bib5]), Australia ([@bib13]), or 8 European countries (multicenter study) ([@bib15]).

###### 

Description of included randomized controlled trials (*n* = 20) that evaluated the success of drugs, diet, and exercise strategies at improving weight-loss maintenance after an initial period of weight loss with a VLCD or LCD (\<1000 kcal/d)[*^1^*](#tblfn1){ref-type="table-fn"}

                                                   Characteristics before weight loss   Weight-loss period (VLCD/LCD)   Weight-loss maintenance period                                                                                                                                                                                                                                                                              
  ------------------------------------------------ ------------------------------------ ------------------------------- --------------------------------------- ------- ----- ----------------- ------- ------- ---------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------ --------------- --------------------- ----------------------------------------------
                                                   *y*                                  *%*                             [*^2^*](#tblfn2){ref-type="table-fn"}   *kg*    *n*   *kcal/d*          *mo*    *kg*                                                                                                                                                                                  *n*             *n*                   *mo*
  Anti-obesity drugs                                                                                                                                                                                                                                                                                                                                                                                                                
   Richelsen, 2007 ([@bib7])                       47                                   51                              37.5                                    111     383   600--800          2       −14.4   Orlistat (360 mg/d)                                                                      Placebo                                                                              309 (153/156)   201 (103/98)          36
   Mathus-Vliegen, 2005 ([@bib6])                  43                                   86                              36.6                                    105     221   480               3       −15.2   Sibutramine (10 mg/d)                                                                    Placebo                                                                              189 (94/95)     120 (62/58)           18
   Apfelbaum, 1999 ([@bib5])                       38                                   79                              38.3                                    104     205   220--800          1       −7.6    Sibutramine (10 mg/d)                                                                    Placebo                                                                              160 (82/78)     108 (60/48)           12
  Diet: protein                                                                                                                                                                                                                                                                                                                                                                                                                     
   Delbridge, 2009 ([@bib13])                      44                                   50                              39.0                                    112     179   500--550          3       −16.5   High protein: 30 E% protein, \<30 E% fat                                                 High carbohydrate: 15 E% protein, \<30 E% fat[*^2^*](#tblfn2){ref-type="table-fn"}   141 (71/70)     82 (42/40)            12
   Claessens, 2009 ([@bib12])                      45                                   65                              32.9                                    97      60    500               1.25    −9.4    High protein: 25 E% protein, 30 E% fat                                                   High carbohydrate: 15 E% protein, 30 E% fat[*^2^*](#tblfn2){ref-type="table-fn"}     54 (NR/NR)      48 (32/16)            3
   Lejeune, 2005 ([@bib16])                        45                                   NR                              29.3                                    83      120   502               1       −6.3    High protein: +30 g/d (∼18--20 E%)                                                       Habitual diet                                                                        113 (53/60)     113 (53/60)           6
   Westerterp-Plantenga, 2004 ([@bib17])           44                                   NR                              29.5                                    87      180   502               1       −6.4    High protein: +48 g/d (∼18--20 E%)                                                       Habitual diet                                                                        150 (NR/NR)     148 (73/75)           3
  Diet: protein and other macronutrients                                                                                                                                                                                                                                                                                                                                                                                            
   Larsen, 2010 ([@bib15])                         42                                   NR                              34.2                                    99      938   800--1000         2       −11     Low protein (13 E%) & low GI                                                             Country-specific dietary guidelines (in all 5 diets: fat 25--30 E%)                  773 (150/154)   548 (106/114)         6.5
                                                                                                                                                                                                                Low protein (13 E%) & high GI                                                            Country-specific dietary guidelines (in all 5 diets: fat 25--30 E%)                  (155/154)       (97/114)              
                                                                                                                                                                                                                High protein (25 E%) & low GI                                                            Country-specific dietary guidelines (in all 5 diets: fat 25--30 E%)                  (159/154)       (124/114)             
                                                                                                                                                                                                                High protein (25 E%) & high GI                                                           Country-specific dietary guidelines (in all 5 diets: fat 25--30 E%)                  (155/154)       (107/114)             
   Due, 2008 ([@bib18])                            28                                   58                              31.5                                    95      154   800--1000         2       −12.8   Healthy Pyramid: 35--45 E% fat, 10--20 E% protein[*^3^*](#tblfn3){ref-type="table-fn"}   Western diet[*^2^*](#tblfn2){ref-type="table-fn"}35 E% fat, 10--20 E% protein        131 (54/26)     106 (39/24)           6
                                                                                                                                                                                                                Low fat: 20--30 E% fat, 10--20 E% protein[*^2^*](#tblfn2){ref-type="table-fn"}           Western diet[*^2^*](#tblfn2){ref-type="table-fn"}35 E% fat, 10--20 E% protein        (51/26)         (43/24)               
  Diet: protein and  supplements                                                                                                                                                                                                                                                                                                                                                                                                    
   Hursel 2009 ([@bib14])                          44                                   55                              29.6                                    85      92    502               1       −7.0    Green tea (2.7 g/d) + protein (10 E%)                                                    Placebo + protein (10 E%)                                                            80 (20/20)      80 (20/20)            3
                                                                                                                                                                                                                Green tea (2.7 g/d) + high protein (20 E%)                                               Placebo + high protein (20 E%)                                                       80 (20/20)      80 (20/20)            3
   Kovacs, 2004 ([@bib19])                         NR                                   75                              29.7                                    85      120   502               1       −6.4    Green tea capsules (2.7 g/d)                                                             Placebo                                                                              104 (51/53)     104 (51/53)           3.25
   Pasman, 1997 ([@bib30])                         41                                   100                             32.9                                    89      49    478               2       −10.7   Fiber supplement (guar gum 20 g/d)                                                       Habitual diet (no fiber supplement)                                                  39 (NR/NR)      20 (10/10)            14
   Kamphuis, 2003 ([@bib25])                       38                                   52                              27.9                                    84      60    502               0.75    −5.9    CLA 1.8 g/d                                                                              Placebo 1.8 g/d                                                                      NR (NR/NR)      54 (14/13)            3.25
                                                                                                                                                                                                                CLA 3.6 g/d                                                                              Placebo 3.6 g/d                                                                      NR (NR/NR)      NR (13/14)            3.25
   Olsson, 2011 ([@bib31])                         48                                   100                             28.3                                    94      54    444--557          1.5     −7.1    Meal replacement for lunch (adding vegetable-oil emulsion; 160 kcal/d)                   Meal replacement for lunch (placebo; containing dairy fat 160 kcal/d)                46 (23/23)      43 (22/21)            3
  Diet: meal replacement and prolonged refeeding                                                                                                                                                                                                                                                                                                                                                                                    
   Gripeteg, 2010 ([@bib20])                       41                                   64                              41.6                                    124     269   479--813          3       −16.5   Prolonged refeeding (6 wk)                                                               Normal refeeding (1 wk)                                                              169 (85/84)     123 (65/58)           10
   Ryttig, 1997 ([@bib10])                         44                                   56                              37.7                                    113     54    420               2       −18.9   Meal replacement (1600 kcal/d; 240 kcal as replacement)                                  Hypocaloric (1600 kcal/d)                                                            54 (27/27)      26 (15/11)            26
   Ryttig, 1995 ([@bib11])                         42                                   80                              39.1                                    112     60    330               3       −20.8   Meal replacement (1600 kcal/d; 220 kcal/d as replacement)                                Hypocaloric (1600 kcal/d)                                                            52 (NR/NR)      45 (23/22)            12
  Diet and exercise                                                                                                                                                                                                                                                                                                                                                                                                                 
   Christensen, 2013 ([@bib26])                    63                                   81                              37.3                                    103.2   192   415--810 + 1200   2 + 2   −12.8   Meal replacement with dietary education (one 137-kcal meal replacement/d)                Usual care                                                                           192 (64/64)     159 (55/52)           12
                                                                                                                                                                                                                Exercise                                                                                 Usual care                                                                           192 (64/64)     159 (52/52)           12
  Exercise                                                                                                                                                                                                                                                                                                                                                                                                                          
   Borg, 2002 ([@bib22])                           43                                   0                               32.9                                    106     90    500               2       −14.3   Walking                                                                                  Diet counseling                                                                      82 (25/29)      68 (25/28/29^6mo^)    6 + 23[*^4^*](#tblfn4){ref-type="table-fn"}
                                                                                                                                                                                                                Exercise                                                                                 Diet counseling                                                                      (28/29)         (20/26/22^23mo^)      
   Fogelholm, 2000 ([@bib23])                      40                                   100                             34.0                                    92      85    646               3       −13.1   Walking: 1004 kcal/wk                                                                    Diet counseling                                                                      82 (26/29)      80 (25/27/28^10mo^)   10 + 24[*^4^*](#tblfn4){ref-type="table-fn"}
                                                                                                                                                                                                                Walking: 2008 kcal/wk                                                                    Diet counseling                                                                      (27/29)         (25/27/28^24mo^)      

CLA, conjugated linoleic acid; Ctrl, control group; E%, percentage of energy; GI, glycemic index; LCD, low-calorie diet; NR, not reported; Trt, treatment group; VLCD, very-low-calorie diet.

In this study, the dietary guidelines group is called "the high-carbohydrate group." The composition of the diet, however, is equivalent to the Nordic Nutrition Recommendations 2004 (55 E% carbohydrates, 15 E% protein, 30 E% fat); hence, it was used as the control group.

Healthy Pyramid corresponds to Willett\'s new Healthy Eating Pyramid, which is high in MUFAs and has a low GI; \>20% of the prescribed fat was MUFAs. The low-fat diet corresponded to the Nordic Nutrition Recommendations (low in fat and a medium GI), and the average Danish diet (similar to the Western diet; high in SUFAs and a high GI) represented the control group.

Unsupervised follow-up.

### VLCD/LCD period

During the weight-loss phase preceding the randomization, 18 of the 20 studies used a VLCD (\<800 kcal/d), whereas 2 studies ([@bib15], [@bib18]) used an LCD of 800 to 1000 kcal/d. Eight of the studies used a strict VLCD, ie, no other food was allowed except for the VLCD powder mixed with water ([@bib6], [@bib7], [@bib10], [@bib11], [@bib20], [@bib22], [@bib23], [@bib25]). In 7 of the studies, the participants were allowed to consume vegetables ([@bib12]--[@bib17], [@bib19]), and in 2 of the studies the powder formulas were mixed with milk ([@bib26]) or a small ad libitum breakfast was allowed within the 800-kcal/d limit ([@bib31]).

### Weight-loss maintenance period

After the weight-loss phase the participants were randomly assigned to a maintenance intervention or a control group. Most (*n* = 11; 55%) of the studies randomly assigned participants only if they had lost 5--10% of the initial weight during the VLCD or LCD period. This applied for all of the drug studies ([@bib5]--[@bib7]) and 8 of the 14 diet studies ([@bib12], [@bib13], [@bib15], [@bib16], [@bib18], [@bib20], [@bib30], [@bib31]) but not for the exercise studies, for which all the participants were randomly assigned despite weight loss.

The duration of the maintenance period ranged from 3 mo to 3 y ([**Figure 2**](#fig2){ref-type="fig"}). Twelve of the 20 studies had a maintenance period of \<1 y, with an overrepresentation of short maintenance periods among the diet studies (10 of 14). All included drug studies had a maintenance period of \>1 y. The 2 studies that studied exercise exclusively had an active maintenance period of \<1 y, but both included a 2-y unsupervised follow-up ([@bib22], [@bib23]).

![Overview of body weight changes in the included randomized controlled trials (*n* = 20) that evaluated different anti-obesity drugs, diet, and exercise weight-loss maintenance strategies after an initial very-low-calorie diet or low-calorie diet (\<1000 kcal/d). CLA, conjugated linoleic acid; GI, glycemic index.](ajcn99114fig2){#fig2}

### Anti-obesity drug studies

Of the 3 anti-obesity drug studies, 2 evaluated sibutramine ([@bib5], [@bib6]) and 1 orlistat ([@bib7]). In 2 ([@bib6], [@bib7]) of the 3 studies, participants in both the intervention and control groups were advised to consume a 600-kcal deficit diet based on their estimated energy expenditure. In the third study the participants were advised to follow the French nutrition guidelines ([@bib5]).

### Diet studies

Of the diet studies/study arms, 6 evaluated a high-protein diet, 6 dietary supplements with a suggested satiating or thermic effect, 4 meal replacements or a prolonged refeeding, and 3 macronutrients other than protein, including low glycemic index, low fat, and eating according to the Healthy Eating Pyramid ([@bib32]).

In addition to the specific maintenance intervention, 10 of the 15 diet studies reported using a co-intervention, such as instructions to the participants to maintain their habitual physical activity levels, dietitian visits, and cooking classes. Two of the studies also supplied the participants with free food from a study supermarket ([@bib15], [@bib18]).

### Exercise studies

The 3 exercise studies ([@bib22], [@bib23], [@bib26]) investigated resistance training, walking, and arthritis-adapted knee exercises, respectively. During the active treatment period, both groups were given dietary counseling based on the LEARN manual ([@bib33]) in the study by Borg et al ([@bib22]), and group meetings were given in the study by Fogelholm et al ([@bib23]); only arthritis-tailored knee exercises were given in the study by Christensen et al ([@bib26]).

Risk of bias
------------

Most studies did not report the randomization process, but simply stated that the participants were randomized. All studies specified the eligibility criteria, and characteristics were similar for the intervention and control groups at randomization in all studies. Seven ([@bib5]--[@bib7], [@bib14], [@bib19], [@bib25], [@bib31]) of the studies were double-blind. Most of the studies only analyzed and reported data on completers, except for the anti-obesity drug studies and the diet and exercise study by Christensen et al ([@bib26]), which analyzed all the included participants. (An intention-to-treat analysis with last observation carried forward analysis for missing data were used in all the anti-obesity drug studies, whereas baseline observation carried forward was used in the diet and exercise study by Christensen et al).

Main findings
-------------

### VLCD/LCD period

During the VLCD or LCD run-in period, before randomization, the pooled mean weight change was −12.4 kg (95% CI: −16.6, −8.2; median weight-loss phase duration: 8 wk) for the anti-obesity drug studies, −11.1 kg (95% CI: −12.1, −10.1; median weight-loss phase duration: 8 wk) for the diet studies, and −13.5 kg (95% CI: −14.0, −13.0 median weight-loss phase duration: 12 wk) for the exercise studies ([**Figure 3**](#fig3){ref-type="fig"}).

![Overview of changes in body weight during the rapid weight-loss phase and the weight-loss maintenance period in 20 randomized controlled trials that evaluated different anti-obesity drug, diet, and exercise weight-loss maintenance strategies after an initial very-low-calorie diet or low-calorie diet (\<1000 kcal/d). The gray lines represent the control subjects in each subcategory. Anti-obesity drugs: sibutramine and orlistat. Dietary supplements: green tea, high fiber, oil supplement, and conjugated linoleic acid. Other macronutrients: low fat, low glycemic index, and Healthy Eating Pyramid. The random-effects model was used to weight and pool the studies within each treatment arm (intervention and control) after the very-low-calorie diet or low-calorie diet period and maintenance period. The mean increase for each month was estimated from these 2 measurements. Weighted mean differences between the intervention and control groups at follow-up were estimated by using a random-effects model.](ajcn99114fig3){#fig3}

### Weight-loss maintenance period

Weight regain during the maintenance period differed between individual studies, ranging from a further mean weight change of −5 kg to a regain of 14 kg in the intervention groups and from −1 kg to a gain of 13 kg in the control groups ([Figure 2](#fig2){ref-type="fig"}).

### Anti-obesity drug studies

Use of an anti-obesity drug compared with placebo improved weight-loss maintenance by 3.5 kg (95% CI: 1.5, 5.5 kg; *P* \< 0.001; median maintenance phase duration: 18 mo; [Figure 3](#fig3){ref-type="fig"} and [**Figure 4**](#fig4){ref-type="fig"}). There was evidence of significant heterogeneity (*I*^2^ = 70%, *P* = 0.04). This heterogeneity was explained by the study by Apfelbaum et al ([@bib5]), in which the participants in the sibutramine arm continued to lose weight during the maintenance period. In a sensitivity analysis that excluded this study, the heterogeneity disappeared (*I*^2^ = 0%, *P* = 0.88).

![Forest plot of control group subtracted weight change (kg) at the end of a weight-loss maintenance program, after an initial very-low-calorie diet or low-calorie diet (\<1000 kcal/d), in 20 randomized controlled trials. Data are weighted mean differences from a random-effects model. Error bars depict 95% CIs. The *I*^2^ statistic refers to heterogeneity. CLA, conjugated linoleic acid; E%, percentage of energy; GI, glycemic index.](ajcn99114fig4){#fig4}

### Diet studies

Overall, the diet maintenance strategies improved weight-loss maintenance by 1.4 kg (95% CI: 0.7, 2.1 kg; *P* \< 0.001; median maintenance phase duration: 6 mo) compared with the control group. A significant degree of heterogeneity (*I*^2^ = 63%, *P* \< 0.001) was explained by the different dietary strategies.

After the dietary studies were stratified into subcategories, extended use of meal replacements and prolonged refeeding improved weight-loss maintenance by 3.9 kg (95% CI: 2.8, 5.5 kg; *P* \< 0.001; median maintenance phase duration: 12 mo) compared with controls. A high-protein diet improved weight-loss maintenance by 1.5 kg (95% CI: 0.8, 2.1 kg; *P* \< 0.001; median maintenance phase duration: 5 mo), nonprotein macronutrients improved weight-loss maintenance by 1.2 kg (95% CI: 0.4, 2.0 kg; *P* = 0.003; median maintenance phase duration: 6 mo), and the use of dietary supplements showed no effect (0.0 kg; 95% CI: −1.4, 1.4 kg; *P* = 0.99; median maintenance phase duration: 3 mo; [Figures 3](#fig3){ref-type="fig"} and [4](#fig4){ref-type="fig"}).

### Exercise

Exercise as compared with diet counseling did not improve weight-loss maintenance (weighted mean difference: 0.8 kg; 95% CI: −1.2, 2.8; *P* = 0.43; median maintenance phase duration: 10 mo). There was significant heterogeneity in the exercise trials (*I*^2^ = 78%, *P* = 0.001), which was explained by the study by Christensen et al ([@bib26]), which had a negative treatment effect, ie, worse weight-loss maintenance ([Figure 4](#fig4){ref-type="fig"}). When only the 2 studies that focused solely on exercise ([@bib22], [@bib23]) were included, weight-loss maintenance was significantly improved (weighted mean difference: 1.6 kg; 95% CI: 0.3, 2.9 kg; *P* = 0.02; median maintenance phase duration: 8 mo; *I*^2^ = 10%, *P* = 0.34). In the analysis of the unsupervised follow-up included in these 2 studies ([@bib22], [@bib23]), weight-loss maintenance was not improved (weighted mean difference: −0.7 kg; 95% CI: −3.0, 1.8; *P* = 0.63; median unsupervised follow-up duration: 24 mo).

Publication bias and meta-regression
------------------------------------

No evidence of publication bias could be detected for any of the maintenance strategies neither based on the Egger\'s test (*P-*drug = 0.28, *P-*diet = 0.88, *P-*exercise = 0.08) nor by visual inspection of funnel plots (*see* Supplemental Figure 1 under "Supplemental data" in the online issue). The heterogeneity within each treatment category was largely diminished after conducting subgroup analyses as described above and was not explained by varying weight-loss magnitudes across the control groups (β: −0.2; 95% CI: −0.4, 0.1; *P* = 0.2) or by differences in study duration when investigated via meta-regression (β: 0.1; 95% CI: −0.2, \<0.1; *P* = 0.2; *see* Supplemental Figure 2 under "Supplemental data" in the online issue).

DISCUSSION
==========

Summary
-------

In this meta-analysis of 20 randomized controlled trials, we found that both anti-obesity drugs and extended use of low-calorie meal replacements improved weight-loss maintenance relative to controls. A high-protein diet was also associated with improved maintenance, although smaller than for meal replacements and drugs. A combined category consisting of low fat, low glycemic index, and the Healthy Eating Pyramid was also associated with improved maintenance, similar in effect to eating a high-protein diet. Exercise and dietary supplementation strategies---such as green tea, high fiber, conjugated linoleic acid, and oil supplementation---were not associated with improved maintenance.

Previous research
-----------------

Previous meta-analyses investigating long-term effects of a VLCD or LCD ([@bib1], [@bib24]) have not included analyses of weight-loss-maintenance strategies. Tsai and Wadden ([@bib1]) included studies that randomly assigned participants to either a VLCD or LCD at baseline. VLCDs were found to induce significantly greater short-term weight change than were LCDs (−16% compared with −10%), but similar long-term changes (−6% compared with −5%) after a 1.9-y follow-up. In most of the included studies, the maintenance programs did not incorporate those strategies that the current meta-analysis identified as being beneficial for weight-loss maintenance (anti-obesity drugs, meal replacements, and high-protein diets).

Anderson et al ([@bib24]) performed a meta-analysis of 29 long-term observational studies using VLCDs or hypoenergetic balanced diets and found that the VLCD group maintained significantly more net weight loss than the hypoenergetic balanced diet participants after 5 y (29% compared with 18%). Indeed, an increasing number of studies now indicate that a substantial initial weight loss predicts a larger long-term net weight loss ([@bib2], [@bib34]--[@bib36]).

In comparison, the current analysis found that most of the weight loss was maintained at the end of follow-up (92% in the protein studies compared with 75% in the control group, 91% in the anti-obesity drug studies compared with 65% in the control group, 86% in the combined category compared with 75% in the control group, 74% in the supplement category compared with 74% in the control group; and 66% compared with 49% in the meal replacement category). However, the mean duration of follow-up in the studies in our meta-analysis of weight maintenance was much shorter (mean follow-up of 5--22 mo, depending on category) than that in the randomized controlled trials in the meta-analyses by Tsai and Wadden ([@bib1]) and Anderson et al ([@bib24]) for all the subgroups, except for the anti-obesity drug studies that had a similar follow-up of 22 mo.

Weight regain was common during the maintenance phase ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}), which highlights the need for an increased understanding of weight-loss defenses. There appear to be ≥3 different drivers behind weight regain after a large weight loss, including adaptive thermogenesis and reduced energy expenditure ([@bib37]), increased circulation of appetite-mediating hormones ([@bib38]), and relapse into old habits ([@bib39]). At least some, if not all, of these defenses are mobilized in relation to weight loss ([@bib40]).

Mechanisms behind improved weight-loss maintenance
--------------------------------------------------

In terms of drug mechanisms, orlistat works by reducing fat uptake, whereas sibutramine reduces appetite. Apart from the 2 randomized controlled trials on sibutramine included in the current meta-analysis, James et al ([@bib41]) also found a large effect of sibutramine on weight-loss maintenance after a 600-kcal/d deficit weight-loss program. Similarly, topiramate (one of the components in Qsymia that is currently approved in the United States)---which acts to reduce energy intake, possibly through increased satiety---has been evaluated specifically for weight-loss maintenance after a VLCD with similar results to sibutramine ([@bib8]), which indicates that other anti-obesity drugs also may improve weight-loss maintenance.

Meal replacements, rich in nutrients but low in caloric content, work both directly and indirectly to reduce energy intake. Because many obese patients underestimate energy intake ([@bib42]), meal replacements can be effective at reducing food choices and therefore facilitate a balanced energy intake. High-protein diets (∼20--30 of energy) have been shown to increase satiety, preserve fat-free mass, and sustain energy expenditure via diet-induced thermogenesis ([@bib43]).

Low-glycemic-index foods may also be beneficial in weight control by increasing satiety and possibly by promoting fat oxidation at the expense of carbohydrate oxidation. Even though we did not find that exercise improved weight-loss maintenance, other studies have found exercise to be effective at promoting long-term weight control ([@bib4], [@bib44]), including after periods of weight loss ([@bib36], [@bib45]). Indeed, 2 of the 3 included randomized controlled trials on exercise in the current study ([@bib22], [@bib23]) indicated improved weight-loss maintenance in the short term. The long-term follow-up data from the same trials were negative, however, probably because of reduced compliance with the high amounts of exercise needed for weight control (60--90 min/d) ([@bib4], [@bib45]).

Limitations and strengths
-------------------------

Our study had several strengths. First, this was the first meta-analysis of randomized controlled trials of weight-loss maintenance strategies after treatment with a VLCD or LCD. Second, we only included randomized controlled trials, meaning they had a low probability of bias and other confounding factors in the original studies. There was also little variation in effect direction, that is, most studies indicated a positive treatment effect. We were also able to directly test the effects of all 3 investigated treatment principles: drugs, diet, and exercise. We also synthesized data from different dietary strategies, which provides clarity in terms of which diets promote weight-loss maintenance. Meta-analysis as a method also allows for greater statistical power than individual trials, which is a common limitation in obesity lifestyle-intervention studies.

There were also benefits of studying maintenance after a VLCD or LCD, as opposed to diets with a higher caloric intake. A VLCD induces a larger short-term weight loss than a does a standard 1500--1800-kcal/d diet ([@bib2]), although there is also more regain ([@bib1], [@bib2]). We were therefore able to analyze data from trials in which a large proportion of participants were likely to regain lost weight.

Our study also had several limitations. Considerable variation was observed in study protocols, mainly relating to type of strategy for preventing weight regain and study duration. Most of the evidence came from dietary strategies, with only 3 randomized controlled trials on the effects of exercise and 3 on anti-obesity drugs. Whereas our analysis clearly supports the use of anti-obesity drugs, 2 of the 3 drug studies were of sibutramine, which was withdrawn in 2010.

A second limitation was in the maintenance-phase duration of the included studies, which varied from 3 to 36 mo ([Figure 3](#fig3){ref-type="fig"}). Because there were so few studies on weight-loss maintenance after a VLCD or LCD, we chose not to include a duration restriction. Hence, short- and long-term studies were assigned equal importance. A third limitation was that most of the studies analyzed only the participants who completed the studies. The anti-obesity drug trials ([@bib5]--[@bib7]) and the diet and exercise study ([@bib26]) were the only studies that provided data from intention-to-treat analyses. The anti-obesity drug studies used last observation carried forward, which includes the last measured value, and, similar to the completers analysis, could lead to an overestimation of the treatment effect. Baseline observation carried forward, which includes the baseline values of each missing value, could on the other hand lead to an underestimation of the treatment effect.

Conclusions
-----------

In this meta-analysis of randomized controlled trials, the largest improvements in weight-loss maintenance after a VLCD or LCD were seen for anti-obesity drugs and meal replacements. A high-protein diet also improved weight-loss maintenance, as did a combined category consisting of low fat, low glycemic index, and the Healthy Eating Pyramid. Exercise and dietary supplements were not associated with improved weight-loss maintenance. Future studies are needed to clarify the potential effect of combining several successful maintenance strategies in obesity-treatment programs.
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